Clinical Insights: January 15, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval No new updates. New Formulation Approval No new updates. New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration…
Join Us at the 340B Coalition Winter Conference!
Join the RxStrategies team at the 340B Coalition Winter Conference in San Diego, California February 21-23. Here, your team can stay up to date on the latest news, trends and regulations in the 340B program to best maintain compliance. We look forward to connecting with industry leaders while gaining insight on 340B happenings and issues…
Clinical Insights: January 2, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Lumify™ (brimonidine tartrate) – New OTC Drug Approval – December 22, 2017 – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary…
Warm Holiday Wishes
Our team at RxStrategies sincerely wishes you warm and happy holidays!
Clinical Insights: December 12, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Lonhala™ Magnair™ (glycopyrrolate) – December 5, 2017 – Sunovion Pharmaceuticals Inc. (Sunovion) announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application…
Ensure and Maximize 340B Program Compliance
We assist retail and specialty pharmacies in ensuring 340B program security, efficiency and safety. With this solution, you will be able to maximize compliance, visibility, capture rate, inventory reconciliation and more. Key Elements of Our Enterprise Backbone for Retail and Specialty Pharmacies • Serves as data clearinghouse for all your contracted TPAs (Third Party…
Clinical Insights: November 13, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] – New Vaccine Approval – November 9, 2017 – Dynavax Technologies Corporation announced that the U.S. Food and Drug Administration…
Clinical Insights: October 24, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Shingrix (Zoster Vaccine Recombinant, Adjuvanted) – New Vaccine Approval – October 20, 2017 – GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has…
Networking in California for the 2017 CFO Forum!
RxStrategies team members Skip Devanny and Tim Vroman are excited to attend the 2017 Health Management Academy (HMA) CFO Forum November 8-11! These executive-focused peer learning forums help senior-level industry leaders network while discussing the latest in health systems research, policy updates and peer case studies. Join our team in Laguna Beach, California as industry…
Clinical Insights: October 16, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval No new updates. New Formulation Approval Lyrica® CR (pregabalin) – October 12, 2017 – Pfizer Inc. announced that the United States Food and Drug Administration…
Clinical Insights: October 10, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Zilretta™ (triamcinolone acetonide extended-release) – October 6, 2017 – Flexion Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Zilretta™ (triamcinolone acetonide extended-release…
Delivering Program Compliance Solutions at the HCP 2017 Fall Hospital Pharmacy Conference!
The RxStrategies’ team is prepped and ready to attend the HCP 2017 Fall Hospital Pharmacy Conference October 16-18 in Chicago, Illinois. The country’s most prestigious hospitals and health systems will be gathering at the Reverse Expo sessions, and our team can’t wait to connect with the Hospital Pharmacy Directors that are attending! Connect with…
- « Previous
- 1
- 2
- 3
- Next »